Literature DB >> 23690235

Prognostic value of survivin expression in breast cancer patients: a meta-analysis.

Jian Song1, Hong Su, Yang-Yang Zhou, Liang-Liang Guo.   

Abstract

The prognostic role of survivin expression in breast cancer patients has been widely reported. However, controversy still remains. Thus, a meta-analysis was conducted to obtain a more precise estimation of the relationship between survivin expression and overall survival (OS) in breast cancer patients. Relevant articles were selected for further assessment by online search in PubMed, EMBASE, and China National Knowledge Infrastructure. Pooled hazard ratios (HR) with 95 % confidence interval (95 % CI) were used to estimate the strength of the association between survivin expression and OS in breast cancer patients. Funnel plots of Begger's and Egger's linear regression test were used to evaluate the publication bias. Heterogeneity and sensitivity analysis were also assessed. Fifteen studies were included in the final analysis with the total number of 2,202 patients. There was a significant association between positive survivin expression and a poor OS consequence in patients with breast cancer (pooled HR 1.80, 95 % CI 1.55-2.09). No significant heterogeneity was observed among all the eligible studies (x (2) = 21.87, p = 0.081, I (2) = 36.0 %). Publication bias was absent. Sensitivity analysis revealed that the results of this meta-analysis were robust. Our results suggested that high survivin expression had an unfavorable prognostic role for patients with breast cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690235     DOI: 10.1007/s13277-013-0848-2

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  62 in total

1.  Expression of survivin and VEGF-C in breast cancer tissue and its relation to lymphatic metastasis.

Authors:  Xiangqi Li; Xianigguo Dang; Xibo Sun
Journal:  Eur J Gynaecol Oncol       Date:  2012       Impact factor: 0.196

2.  Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total survivin in breast cancer?

Authors:  Paul N Span; Vivianne C G Tjan-Heijnen; Joop J T M Heuvel; Jacques B de Kok; John A Foekens; Fred C G J Sweep
Journal:  Clin Chem       Date:  2006-07-27       Impact factor: 8.327

3.  Expression of COX-2, survivin in regional lymph node metastases of gastric carcinoma and the correlation with prognosis.

Authors:  Yong Li; Bi-bo Tan; Li-qiao Fan; Qun Zhao; Yu Liu; Dong Wang
Journal:  Hepatogastroenterology       Date:  2010 Nov-Dec

Review 4.  Lymphatic microvessel density and vascular endothelial growth factor-C and -D as prognostic factors in breast cancer: a systematic review and meta-analysis of the literature.

Authors:  Jun Wang; Yan Guo; Baocheng Wang; Jingwang Bi; Kainan Li; Xiuju Liang; Huili Chu; Huihui Jiang
Journal:  Mol Biol Rep       Date:  2012-10-11       Impact factor: 2.316

Review 5.  The role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis.

Authors:  Qian Qian; Qian Wang; Ping Zhan; Ling Peng; Shu-Zhen Wei; Yi Shi; Yong Song
Journal:  Cancer Invest       Date:  2010-07       Impact factor: 2.176

6.  Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy.

Authors:  Romain Boidot; Frédérique Vegran; Sarab Lizard-Nacol
Journal:  Int J Mol Med       Date:  2009-02       Impact factor: 4.101

7.  Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.

Authors:  Sandra E Ghayad; Julie A Vendrell; Ivan Bieche; Frédérique Spyratos; Charles Dumontet; Isabelle Treilleux; Rosette Lidereau; Pascale A Cohen
Journal:  J Mol Endocrinol       Date:  2008-11-04       Impact factor: 5.098

8.  Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis.

Authors:  Meilan Chen; Erhui Cai; Jizheng Huang; Ping Yu; Ke Li
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-05-07       Impact factor: 4.254

9.  Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of survivin.

Authors:  Gamze Gokoz Dogu; Metin Ozkan; Figen Ozturk; Mustafa Dikilitas; Ozlem Er; Ahmet Ozturk
Journal:  Med Oncol       Date:  2009-01-21       Impact factor: 3.064

10.  Practical methods for incorporating summary time-to-event data into meta-analysis.

Authors:  Jayne F Tierney; Lesley A Stewart; Davina Ghersi; Sarah Burdett; Matthew R Sydes
Journal:  Trials       Date:  2007-06-07       Impact factor: 2.279

View more
  17 in total

1.  Resistance to the mTOR inhibitor everolimus is reversed by the downregulation of survivin in breast cancer cells.

Authors:  Ludovica Taglieri; Francesca De Iuliis; Anna Giuffrida; Sabrina Giantulli; Ida Silvestri; Susanna Scarpa
Journal:  Oncol Lett       Date:  2017-07-18       Impact factor: 2.967

2.  Gene expression profiling of anti-CTLA4-treated metastatic melanoma in patients with treatment-induced autoimmunity.

Authors:  Scott C Bresler; Le Min; Scott J Rodig; Andrew C Walls; Shuyun Xu; Songmei Geng; F Stephen Hodi; George F Murphy; Christine G Lian
Journal:  Lab Invest       Date:  2016-12-05       Impact factor: 5.662

3.  Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.

Authors:  Giuseppina Salzano; Gemma Navarro; Malav S Trivedi; Giuseppe De Rosa; Vladimir P Torchilin
Journal:  Mol Cancer Ther       Date:  2015-02-05       Impact factor: 6.261

4.  Multi-antigen-targeted T-cell therapy to treat patients with relapsed/refractory breast cancer.

Authors:  Valentina Hoyos; Spyridoula Vasileiou; Manik Kuvalekar; Ayumi Watanabe; Ifigeneia Tzannou; Yovana Velazquez; Matthew French-Kim; Wingchi Leung; Suhasini Lulla; Catherine Robertson; Claudette Foreman; Tao Wang; Shaun Bulsara; Natalia Lapteva; Bambi Grilley; Matthew Ellis; Charles Kent Osborne; Angela Coscio; Julie Nangia; Helen E Heslop; Cliona M Rooney; Juan F Vera; Premal Lulla; Mothaffar Rimawi; Ann M Leen
Journal:  Ther Adv Med Oncol       Date:  2022-07-15       Impact factor: 5.485

5.  Expression of survivin does not appear to influence breast cancer recurrence risk.

Authors:  Lindsay J Collin; Deirdre P Cronin-Fenton; Thomas P Ahern; Kristina B Christensen; Per Damkier; Stephen Hamilton-Dutoit; Anders Kjaersgaard; Kristina L Lauridsen; Rami Yacoub; Peer Christiansen; Henrik Toft Sørensen; Timothy L Lash
Journal:  Acta Oncol       Date:  2018-10-23       Impact factor: 4.089

6.  Expression of survivin mRNA in gallbladder cancer: a diagnostic and prognostic marker?

Authors:  Jaya Nigam; Abhijit Chandra; Hasan Raza Kazmi; Devendra Parmar; Devendra Singh; Vishal Gupta; Noushif M
Journal:  Tumour Biol       Date:  2014-06-17

7.  The expression of Survivin and NF-κB associated with prognostically worse clinicopathologic variables in hepatocellular carcinoma.

Authors:  Yi Jin; Jianning Chen; Zhiying Feng; Wenzhe Fan; Yu Wang; Jiaping Li; Dayue Tong
Journal:  Tumour Biol       Date:  2014-07-05

Review 8.  Monitoring survivin expression in cancer: implications for prognosis and therapy.

Authors:  Rodrigo Santa Cruz Guindalini; Maria Cecília Mathias Machado; Bernardo Garicochea
Journal:  Mol Diagn Ther       Date:  2013-12       Impact factor: 4.074

9.  Do fasudil and Y-27632 affect the level of transient receptor potential (TRP) gene expressions in breast cancer cell lines?

Authors:  Bulent Gogebakan; Recep Bayraktar; Ali Suner; Ozan Balakan; Mustafa Ulasli; Muzeyyen Izmirli; Serdar Oztuzcu; Celaletdin Camci
Journal:  Tumour Biol       Date:  2014-05-18

10.  Prognostic Significance of BIRC5/Survivin in Breast Cancer: Results from Three Independent Cohorts.

Authors:  Nina Oparina; Malin C Erlandsson; Anna Fäldt Beding; Toshima Parris; Khalil Helou; Per Karlsson; Zakaria Einbeigi; Maria I Bokarewa
Journal:  Cancers (Basel)       Date:  2021-05-04       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.